ceftriaxone + linezolid + meropenem

This is a combination of three antibiotics—ceftriaxone, linezolid, and meropenem—used together for the treatment of severe or resistant bacterial infections. - **Ceftriaxone** is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. It is active against many Gram-negative and some Gram-positive bacteria[3]. - **Linezolid** is an oxazolidinone antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex in bacterial translation. It is primarily used for multi-resistant Gram-positive infections such as MRSA and VRE[1][2]. - **Meropenem** is a carbapenem antibiotic with broad-spectrum activity against both Gram-negative and Gram-positive bacteria; it also acts by inhibiting cell wall synthesis through binding to penicillin-binding proteins. Meropenem is often reserved for severe or high-risk infections due to its potency against resistant organisms[5][9]. The combination may be considered in cases where multidrug-resistant organisms are suspected or confirmed, particularly in critically ill patients (e.g., sepsis, meningitis) when monotherapy may not be sufficient or when synergistic effects are desired[1][2].